Weight loss and body composition after compounded semaglutide treatment in a real world setting
Diabetes, Obesity and Metabolism · 2025-03 · 27 (3) · 1536-1543
DOI: 10.1111/dom.16162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 07.01.2025. Verfasst von Elizabeth Chun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Statistics, Texas A&M University, College Station, Texas, USA. Hauptthemen laut MEDLINE: Body Composition, Weight Loss, Glucagon-Like Peptides, Obesity. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Introduction
Clinical trials have shown efficacy of semaglutide for weight loss, but further study is needed in less controlled environments including impacts on body composition. Materials and Methods This retrospective study included individuals who participated in a weight management programme at a commercial wellness studio receiving once‐weekly compounded semaglutide/cyanocobalamin injections from June 2023 to January 2024. Once‐weekly semaglutide/cyanocobalamin injected subcutaneously starting at 0.25 mg/0.125 mg and titrated to a maximum dose of 2.4 mg/0.24 mg. The primary endpoint was weight loss at 3 months, with secondary analyses including weight loss percentage, weight loss by body mass index (BMI) class and body composition changes including changes in total fat mass, lean body mass, skeletal muscle mass and trunk adiposity.
Results
A total of 94 individuals were analysed (81F/13M), age in years mean (SD) = 46.57 (10.60). After 3 months, average weight loss was 4.11 (2.77) kg or 4.57% (2.96%). Individuals lost fat mass (2.67 (2.37) kg) and trunk fat mass (1.10 (1.36) kg), while also losing small amounts of lean mass (1.43 (1.41) kg) and skeletal muscle mass (0.88 (0.81) kg). As a proportion of total weight, fat mass decreased while lean muscle mass and skeletal muscle mass increased.
Discussion
This study demonstrates that meaningful weight loss is achievable on semaglutide/cyanocobalamin outside of a closely controlled environment. In addition, body composition improved with losses in fat mass and gains in overall proportion of lean muscle and skeletal muscle.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Statistics, Texas A&M University, College Station, Texas, USA.
- Restore Hyper Wellness, Austin, Texas, USA.
- University of Connecticut, Storrs, Connecticut, USA.
- Division of Preventive Medicine, Mass General Brigham, Boston, Massachusetts, USA.
- Stanford Lifestyle Medicine, Stanford Prevention Research Center, Department of Medicine, Stanford University, Stanford, California, USA.
ORCID-Profile: Rachele Pojednic
Zitieren
APA
Chun, E., Siojo, A., Rivera, D., Reyna, K., Legere, H., Joseph, R., & Pojednic, R. (2025). Weight loss and body composition after compounded semaglutide treatment in a real world setting. Diabetes, Obesity and Metabolism, 27(3), 1536-1543. https://doi.org/10.1111/dom.16162
Vancouver
Chun E, Siojo A, Rivera D, Reyna K, Legere H, Joseph R, et al. Weight loss and body composition after compounded semaglutide treatment in a real world setting. Diabetes, Obesity and Metabolism. 2025;27(3):1536-1543. doi:10.1111/dom.16162
BibTeX
@article{Chun2025,
author = {Chun, Elizabeth and Siojo, Alexandra and Rivera, David and Reyna, Kirsten and Legere, Henry and Joseph, Richard and Pojednic, Rachele},
title = {Weight loss and body composition after compounded semaglutide treatment in a real world setting},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {3},
pages = {1536--1543},
doi = {10.1111/dom.16162}
}
EUVIMED